SCYNEXIS is part of the drug manufacturers industry and trades as part of the healthcare sector. SCYNEXIS Inc is a pharmaceutical company engaged in the discovery, development, and commercialization of novel anti-infectives to address unmet therapeutic needs.

Previous Intraday Performance:

The SCYX shares had a previous change of -0.79% which opened at 1.25 and closed at 1.26. It moved to an intraday high of 1.30 and a low of 1.23.

PR Newswire:  SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note

Historical Performance:

Over the last five trading days, SCYX shares returned 0.80% and in the past 30 trading days it returned 75.00%. Over three months, it changed 117.20%. In one year it has changed -13.70% and within that year its 52-week high was 2.15 and its 52-week low was 0.35. SCYX stock is 260.00% above its 52 Week Low.

Our calculations result in a 200 day moving average of 1.21 and a 50 day moving average of 1.02. Right now, SCYX stock is trading 3.74% above its 200 day moving average and may be a good opportunity to buy.

PR Newswire:  SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note


The company has a market cap of $60.4m with 48.0m shares outstanding and a float of 46.7m shares. Trading volume was 303,019 shares and has experienced an average volume of 1,920,479 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for SCYNEXIS was -0.99 which ended on 31st of December 2017. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.09.

Below was the last reported quarterly earnings per share:
12-31-2018:  -0.09 (estimated)
09-30-2018:  -0.14
06-30-2018:  -0.23
03-31-2018:  -0.12

Base on our calculations, the intrinsic value per share is 4.17, which means it might be undervalued and has a margin of safety of 69.80%

The next earnings report will be: 03-20-2019

The growth of the EPS is critical in understanding the current valuation of SCYNEXIS; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -40.00% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 57.20% of institutional ownership.

I calculated the beta to be 2.34

Business Wire:  Prana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System Atrophy

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -80.20%, return on assets is -43.67%, price-to-sales is 315.67 and price-to-book is 2.19.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 3  : Valuation Result
 0  : Dividend Safety Result
 3  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here